A carregar...
A Phase I Study of a Combination of Yttrium-90 labeled Anti-CEA Antibody and Gemcitabine in Patients with CEA Producing Advanced Malignancies
PURPOSE: To determine the maximum tolerated dose of combined therapy using an yttrium-90 labeled anti-CEA antibody with gemcitabine in patients with advanced CEA producing solid tumors. EXPERIMENTAL DESIGN: The chimeric human/murine cT84.66 is an anti-CEA intact IgG1, with high affinity and specific...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3248239/ https://ncbi.nlm.nih.gov/pubmed/19351765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2213 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|